

The Use of Thermo-Switchable Hydrophobic Deep Eutectic Solvent for CuAAC reactions.

Florence Charnet Pouget, Jean-Michel Andanson, Arnaud Gautier



Université Clermont Auvergne, CNRS, ICCF, F-63000 Clermont–Ferrand, France.

Electronic Supplementary Information



S1-NMR spectrum.	16
S1.1. 2-(2-(2-azidoethoxy)ethoxy)ethanol.	16
S1.2. 1-β-D-galactopyranosyl azide.	17
S1.3. 1-O-Propargyl-D-Mannose.	18
S1.4. 3-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)propan-1-ol, 3a	19
S1.4. 3-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)propan-1-ol, 4	20
S1.5. 3-(4-(hydroxypropyl)-1H-1,2,3-triazol-1-yl)propan-1-ol, 5	21
S1.6. 2-(2-(2-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)ethoxy) ethoxy) ethanol, 6	22
S1.7. (1-benzyl-1H-1,2,3-triazol-4-yl)methanol, 7	23
S1.8. 6-((1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl)-α-mannopyranose, 8	24
S1.9. 6-((1-(3-benzyl)-1H-1,2,3-triazol-4-yl)-α-mannopyranose, 1TFA, 9	25
S1.10. (1-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl))-α-mannopyranose, 10	26
S1.11. 6-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl))-β-galactopyranose, 11	27
S1.12. ((β-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl) methylene α-D-mannopyranose, 13	28
S2-Amount of lidocaine in the aqueous layer versus amount of catalyst used.	30

S1-NMR spectrum.


S1.1. 2-(2-(2-azidoethoxy)ethoxy)ethanol.





S1.2. 1- β -D-galactopyranosyl azide.




S1.3. 1-O-Propargyl-D-Mannose.





S1.4. 3-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)propan-1-ol, **3a**.





S1.4. 3-(4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)propan-1-ol, **4**.



S1.5. 3-(4-(hydroxypropyl)-1H-1,2,3-triazol-1-yl)propan-1-ol, **5**.




S1.6. 2-(2-(2-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy) ethanol, **6**.




S1.7. (1-benzyl-1H-1,2,3-triazol-4-yl)methanol, 7.



Aqueous layer: ^1H NMR in D_2O





DES layer: ^1H NMR in $\text{dms}_\text{o}_\text{d}_6$





S1.8. 6-((1-(3-hydroxypropyl)-1H-1,2,3-triazol-4-yl)- α -mannopyranose, **8**.





S1.9. 6-((1-(3-benzyl)-1H-1,2,3-triazol-4-yl)- α -mannopyranose, 1TFA, **9**.




S1.10. (1-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)- α -mannopyranose, **10**.




S1.11. 6-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl))- β -galactopyranose, **11**.




S1.12. ((β -D-galactopyranosyl)-1H-1,2,3-triazol-4-yl) methylene α -D-mannopyranose, **13**.




$^{13}\text{C}\{^1\text{H}\}$ (100MHz, dmsO-d_6):



Jmode (100MHz, dmso-d₆):



COSY (dmso-d₆):



S2-Amount of lidocaine in the aqueous layer versus amount of catalyst used.

